ANVRX
Price
$11.62
Change
+$0.14 (+1.22%)
Updated
Aug 21 closing price
Net Assets
533.2M
VIHAX
Price
$50.90
Change
+$0.55 (+1.09%)
Updated
Aug 21 closing price
Net Assets
21.87B
Interact to see
Advertisement

ANVRX vs VIHAX

ANVRX vs VIHAX Comparison Chart in %
View a ticker or compare two or three
VS
ANVRX vs. VIHAX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANVRX is a Buy and VIHAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VIHAX has more cash in the bank: 21.9B vs. ANVRX (533M). VIHAX pays higher dividends than ANVRX: VIHAX (3.45) vs ANVRX (2.91). ANVRX was incepted earlier than VIHAX: ANVRX (7 years) vs VIHAX (10 years). ANVRX (1.68) is less costly to investors than VIHAX (0.16). ANVRX is a more actively managed with annual turnover of: 71.00 vs. VIHAX (9.00). ANVRX has a lower initial minimum investment than VIHAX: ANVRX (2500) vs VIHAX (3000). VIHAX annual gain was more profitable for investors over the last year : 25.96 vs. ANVRX (14.50). VIHAX return over 5 years is better than : 66.41 vs. ANVRX (31.64).
ANVRXVIHAXANVRX / VIHAX
Total Expense Ratio1.680.161,050%
Annual Report Gross Expense Ratio1.680.161,050%
Fund Existence7 years10 years-
Gain YTD13.69917.60178%
Front LoadN/AN/A-
Min. Initial Investment2500300083%
Min. Initial Investment IRAN/AN/A-
Net Assets533M21.9B2%
Annual Yield % from dividends2.913.4584%
Returns for 1 year14.5025.9656%
Returns for 3 years28.3775.6338%
Returns for 5 years31.6466.4148%
Returns for 10 yearsN/A108.07-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMOCX19.250.23
+1.21%
Victory RS Mid Cap Growth C
CIVHX22.290.17
+0.77%
American Funds Intl Vntg 529-F-3
GSYPX45.930.22
+0.48%
Goldman Sachs Small Cap Value P
PASTX68.290.18
+0.26%
T. Rowe Price Science & Tech Adv
JMNCX12.25-0.01
-0.08%
JPMorgan Research Market Neutral C